Related Experiment Video
Updated: May 10, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Optimal duration of anticoagulation after left atrial appendage closure: a systematic review and meta-analysis
Xuan Lu1, Zhenyu Yang1, Wei Fang1
1Department of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
Insights
Forty-five days of post-procedure anticoagulation after left atrial appendage closure (LAAC) is as effective as 3 months for preventing stroke and device thrombosis. This shorter duration significantly reduces major bleeding events in patients with atrial fibrillation.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Left atrial appendage closure (LAAC) is a key stroke prevention strategy for nonvalvular atrial fibrillation patients unsuitable for anticoagulation.
- Optimal anticoagulation duration post-LAAC remains uncertain, impacting patient management and outcomes.
- This study addresses the need for evidence-based guidelines on post-LAAC anticoagulant therapy duration.
Purpose of the Study:
- To evaluate the optimal duration of novel oral anticoagulant (NOAC) treatment following left atrial appendage closure (LAAC).
- To compare the efficacy and safety of 45-day versus 3-month NOAC treatment regimens post-LAAC.
Main Methods:
- A comprehensive meta-analysis was conducted, searching PubMed, Embase, Cochrane Library, and Web of Science databases.
- Included studies focused on LAAC procedures and were published up to December 20, 2023.
- The analysis compared outcomes of 45-day and 3-month postoperative NOAC treatment durations.
Main Results:
- No significant differences were observed in the incidence of stroke/transient ischemic attack (TIA) or device-related thrombus between the 45-day and 3-month NOAC groups.
- The incidence of major bleeding was significantly lower in the 45-day NOAC treatment group compared to the 3-month group (P < 0.01).
- Four prospective and ten retrospective cohort studies, totaling 14 studies, were included in the meta-analysis.
Conclusions:
- A 45-day postoperative anticoagulation regimen following LAAC significantly reduces major bleeding risk.
- This shorter duration maintains comparable efficacy in preventing stroke, TIA, and device-related thrombus compared to a 3-month regimen.
- Findings support a 45-day NOAC treatment duration as a potentially safer and equally effective strategy post-LAAC.
Background:
Left atrial appendage closure (LAAC) has become the treatment of choice for stroke prevention in patients with nonvalvular atrial fibrillation who are at high risk of bleeding or with contraindications for anticoagulation. However, the optimal duration of anticoagulation after LAAC remains uncertain. The aim of this study was to evaluate the optimal duration of treatment with novel oral anticoagulants (NOACs) after LAAC.
Method:
We searched the PubMed, Embase, Cochrane Library, and Web of Science databases for studies related to LAAC published from inception to 20 December 2023, and performed a meta-analysis comparing the efficacy and safety of 45-day and 3-month postoperative NOAC treatment using R4.3.1 software.
Results:
A total of 14 studies were included in this study, of which 4 were prospective cohort studies and 10 were retrospective cohort studies. The incidence of stroke or transient ischaemic attack (0.018 [95% CI: 0.007-0.033] in the 3-month group and 0.005 [95% CI: 0.001-0.011] in the 45-day group; P = 0.07) and the incidence of device-related thrombus (0.025 [95% CI: 0.002-0.065] in the 3-month group and 0.020 [ 95% CI: 0.007-0.037] in the 45-day group; P = 0.81) were not significantly different. However, the incidence of major bleeding was significantly greater in the 3-month group than in the 45-day group (0.033 [95% CI: 0.018-0.053] in the 3-month group and 0.003 [95% CI: 0.000-0.008] in the 45-day group; P < 0.01).
Conclusions:
Compared with the 3-month scheme, 45 days of postoperative anticoagulation significantly reduced the risk of major bleeding in patients without compromising the efficacy of preventing stroke or transient ischaemic attack and device-related thrombus.
Trial Registration:
Our meta-analysis was registered in the PROSPERO international database (CRD42024524661).
